Sotrovimab Monoclonal Antibody Treatment for COVID-19

As of April 5, 2022, the U.S. Food and Drug Administration (FDA) reissued the emergency use authorization (EUA) for GSK-Vir Biotechnology’s sotrovimab monoclonal antibody treatment. It is important to note Sotrovimab is no longer authorized for use within the U. S. The full FDA press release can be read at FDA updates Sotrovimab emergency use authorization | FDA

Corresponding revisions have been made to the authorized fact sheets for sotrovimab which can be found on the FDA’s website GSK Sotrovimab Fact Sheet for HCP 03252022 (fda.gov)

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest